文献速递胸部介入CT

经皮影像引导微波消融与冷冻消融治疗肉瘤肺转移的10年经验比较

Comparison of Percutaneous Image-Guided Microwave Ablation and Cryoablation for Sarcoma Lung Metastases: A 10-Year Experience.
PubMed 文献 · AJR Am J Roentgenol · 2021-10-06

这项回顾性队列研究纳入27例患者共39次CT引导经皮消融(21次MWA,18次冷冻消融)治疗65个肉瘤肺转移灶,比较技术成功、并发症、局部肿瘤控制和总生存。两种方式原发技术成功率均为97%,消融方式和肿瘤位置与局部进展无关,肿瘤≤1 cm与局部进展累积发生率降低相关(p=.048),无危及生命的并发症。

要点

  • MWA与冷冻消融治疗肉瘤肺转移的原发技术成功率均为97%。
  • 肿瘤≤1 cm与局部进展累积发生率降低独立相关(p=.048)。
  • 消融方式(p=.86)和肿瘤位置(p=.54)与局部进展无关。

局限性

  • 回顾性研究设计
  • 单中心
  • 样本量较小(27例患者,65个肿瘤)

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. To our knowledge, outcomes between percutaneous microwave ablation (MWA) and cryoablation of sarcoma lung metastases have not been compared. OBJECTIVE. The purpose of this study was to compare technical success, complications, local tumor control, and overall survival (OS) after MWA versus cryoablation of sarcoma lung metastases. METHODS. This retrospective cohort study included 27 patients (16 women, 11 men; median age, 64 years; Eastern Cooperative Oncology Group performance score, 0-2) who, from 2009 to 2021, underwent 39 percutaneous CT-guided ablation sessions (21 MWA and 18 cryoablation sessions; one to four sessions per patient) to treat 65 sarcoma lung metastases (median number of tumors per patient, one [range, one to 12]; median tumor diameter, 11.0 mm [range, 5-33 mm]; 25% of tumors were nonperipheral). We compared complications according to ablation modality by use of generalized estimating equations. We evaluated ablation modality, tumor size, and location (peripheral vs nonperipheral) in relation to local tumor progression by use of proportional Cox hazard models, with death as the competing risk. We estimated OS using the Kaplan-Meier method. RESULTS. Primary technical success was 97% for both modalities. Median follow-up was 23 months (range, one to 102 months; interquartile range, 12-44 months). A total of seven of 61 tumors (11%) showed local progression. Estimated 1-year and 2-year local control rates were, for tumors 1 cm or smaller, 97% and 95% after MWA versus 99% and 98% after cryoablation, and for tumors larger than 1 cm, 74% and 62% after MWA versus 86% and 79% after cryoablation. Tumor size of 1 cm or smaller was associated with a decreased cumulative incidence of local progression (p = .048); ablation modality and tumor location were not associated with progression (p = .86 and p = .54, respectively). Complications (Common Terminology Criteria for Adverse Events [CTCAE] grade, ≤ 3) occurred in 17 of 39 sessions (44%), prompting chest tube placement in nine (23%). There were no CTCAE grade 4 or 5 complications. OS at 1, 2, and 3 years was 100%, 89%, and 82%, respectively. CONCLUSION. High primary technical success, local control, and OS support the use of MWA and cryoablation for treating sarcoma lung metastases. Ablation modality and tumor location did not affect local progression. The rate of local tumor progression was low, especially for small tumors. No life-threatening complications occurred. CLINICAL IMPACT. Percutaneous MWA and cryoablation are both suited for the treatment of sarcoma lung metastases, especially for tumors 1 cm or smaller, whether peripheral or nonperipheral. Complications, if they occur, are not life-threatening.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Bourgouin PP, Wrobel MM, Mercaldo ND, et al. Comparison of Percutaneous Image-Guided Microwave Ablation and Cryoablation for Sarcoma Lung Metastases: A 10-Year Experience. AJR Am J Roentgenol. 2021. PMID: 34612679. doi:10.2214/AJR.21.26551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。